PHRHealthcare · Health Information ServicesThe 18 Wall Street analysts covering Phreesia, Inc. hold a median 12-month price target of $14 — +29.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 12 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Phreesia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (92): The business earns solid, repeatable profits on what it owns.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | Raymond James | Downgrade | Market Perform | — |
| 4 Sept 2026 | Baird | Maintains | Neutral | $10 → $11 |
| 4 Sept 2026 | DA Davidson | Maintains | Buy | $14 → $13 |
| 3 Sept 2026 | Canaccord Genuity | Maintains | Buy | $16 |
| 3 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $14 |
| 3 Sept 2026 | Needham | Reiterates | Buy | $14 |
| 3 Sept 2026 | RBC Capital | Reiterates | Outperform | $19 |
| 3 Sept 2026 | Wells Fargo | Maintains | Equal-Weight | $9.00 → $10 |
| 31 Aug 2026 | Needham | Reiterates | Buy | $14 |
| 31 Aug 2026 | Needham | Reiterates | Buy | — |
| 29 May 2026 | Truist Securities | Maintains | Hold | $11 → $12 |
| 29 May 2026 | Truist Securities | Maintains | Hold | — |
| 28 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 May 2026 | Canaccord Genuity | Maintains | Buy | $22 → $16 |
| 28 May 2026 | Citigroup | Maintains | Neutral | $10 → $12 |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | DA Davidson | Maintains | Buy | $14 |
| 28 May 2026 | DA Davidson | Maintains | Buy | — |
| 20 May 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 15 May 2026 | Barclays | Downgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Phreesia, Inc. returned −51.4% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 11% of US stocks
Cheaper than 62% of US stocks
Cheaper than 48% of US stocks
Cheaper than 22% of US stocks
Higher than 53% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 57% of US stocks
Higher than 52% of US stocks
Higher than 50% of US stocks
Higher than 63% of US stocks
Higher than 98% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Phreesia, Inc. has a market value of $671.6M and an enterprise value of $666.6M.
Revenue in the twelve months to 31 July 2026: $507.8M. The latest quarter grew 10.4% year on year.
Net income over the same four quarters: $10.4M, a 2.1% net margin.
Diluted earnings per share, trailing twelve months: $0.17.
Free cash flow in the twelve months to 31 July 2026: $67.5M, after $13.2M of capital spending.
Trailing P/E: 63.6×; forward P/E: 6.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 20.79%, paying out 0% of earnings.
Phreesia, Inc. employs 1,789 people — $284K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Phreesia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Phreesia announced that Michael Rasbury, VP of AccessOne Solutions, was named to Becker’s Hospital Review’s 2026 Rising Stars: Healthcare Leaders Under 40 list.
Why it matters — The recognition highlights a Phreesia leader and the company’s AccessOne Solutions business.
Phreesia has been named to TIME's 2026 list of the World's Top HealthTech Companies, developed in partnership with Statista, marking its second consecutive year on the list. The recognition highlights companies using technology to make healthcare more effective and accessible across six health technology market segments.
Why it matters — For PHR watchers, this second consecutive industry recognition lends external validation of the company's positioning and technological standing in the healthcare technology space.
Phreesia announced that its ProviderConnect audiences are now available in the DeepIntent Audience Marketplace. This expands the distribution of Phreesia's healthcare audience data through DeepIntent's platform.
Why it matters — A PHR watcher would care because the move broadens the reach of Phreesia's data offerings, potentially extending its advertising and audience product to a new marketplace channel.
Phreesia's stock declined today amid lingering negative sentiment following the company's latest earnings release, as investors reacted negatively to the company missing its earnings expectations.
Why it matters — A PHR watcher would care because the stock's decline reflects investor disappointment over the company's latest earnings miss, which may signal ongoing concerns about its financial performance.
Phreesia's stock fell despite a sharp rise in net income, as results missed analysts' expectations. The company did slightly beat consensus estimates for revenue.
Why it matters — The stock decline despite an earnings beat on revenue signals that market watchers may be more focused on profit expectations for Phreesia.
The 18 Wall Street analysts covering Phreesia, Inc. have a median 12-month price target of $14, with estimates ranging from $10 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Phreesia, Inc., 10 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phreesia, Inc. 56 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Phreesia, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +29.4% from the last close, and Ticker Nerd's factor model ranks Phreesia, Inc. 56 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Phreesia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $20 over the next 12 months.
Phreesia, Inc. returned -51.4% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Phreesia Inc. is a healthcare technology company that provides an integrated software and payments platform for medical practices, health systems, and other healthcare organizations.
The most recent item we track (Business Wire, 8 Oct 2026): "Phreesia's Michael Rasbury Named to Becker's 2026 List of Rising Stars: Healthcare Leaders Under 40". Phreesia announced that Michael Rasbury, VP of AccessOne Solutions, was named to Becker’s Hospital Review’s 2026 Rising Stars: Healthcare Leaders Under 40 list.
Phreesia Inc. is a healthcare technology company that provides an integrated software and payments platform for medical practices, health systems, and other healthcare organizations. Its products support patient intake, registration, scheduling, eligibility verification, payments, and post-visit engagement, helping providers streamline front-office and administrative workflows. The company also offers patient activation, clinical assessments, and communication tools that help organizations capture information more efficiently and improve care coordination. Phreesia serves a wide range of healthcare customers, including ambulatory practices, specialty groups, hospitals, life sciences companies, and payers. Its platform is used across patient check-in and revenue cycle processes, making Phreesia a key provider of digital infrastructure in healthcare operations.
CEO Mr. Chaim Indig · 1,789 employees · United States · https://www.phreesia.com
